Imricor Medical Systems (ASX:IMR) said all technical goals of the sensing and image-guided neurological therapies, cardiac electrophysiology, and tumor Treatments consortium related to its NorthStar 3D mapping system operating on Philips Medical Systems' MRI platform were achieved during testing, according to a Thursday filing with the Australian Securities Exchange.
The testing was conducted over 14 hours at Amsterdam University Medical Center on Oct. 10, the filing said.
Philips and the company are now working on full commercialization efforts for NorthStar on the Philips platform, according to the filing.
Imricor Medical Systems' shares rose 8% in morning trade Friday and earlier hit their highest since January 2022.
Price (AUD): $0.80, Change: $+0.060, Percent Change: +8.11%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.